The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In comments to the committee for a hearing on supply chains, the AHA called for tariff exceptions to continue for pharmaceuticals and pharmaceutical products and that additional exceptions be added for medical devices and other critical care supplies.   
  
“Mitigating supply chain challenges requires diversifying where raw materials are sourced and where products are manufactured,” the AHA wrote. “Imposing tariffs that limit the U.S.’s ability to acquire constituent parts or finished medical and pharmaceutical products from abroad will hinder supply chain resiliency.”  
  
The AHA also urged Congress to reintroduce the Mapping America’s Pharmaceutical Supply Act, legislation that would create a plan for the Food and Drug Administration and the Department of Defense to map the U.S. pharmaceutical supply chain, and the Pharmaceutical Supply Chain Risk Assessment Act, a bill that would require a comprehensive risk assessment of the pharmaceutical supply chain. 

Related News Articles

Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…
Chairperson's File
Public
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…